جميع الدراسات
التوظيفالمرحلة 2تدخلي

Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder

This research study is investigating a drug called inebilizumab for children and adolescents between 2 and 17 years old who have a rare condition called Neuromyelitis Optica Spectrum Disorder (NMOSD). These young people must also have specific antibodies in their blood called AQP4-IgG. The main goals of the study are to understand how the medicine moves through the body (pharmacokinetics), what effects it has on the body (pharmacodynamics), and how safe it is. Participants will receive the medicine intravenously over 28 weeks, and their health will be closely monitored throughout the study, which could last up to 80 weeks.

نظرة سريعة

الحالة
التوظيف
المرحلة
المرحلة 2
الراعي
Amgen
الهدف من التسجيل
15
ابدأ
03 يوليو 2023
التاريخ المتوقع للانتهاء
13 Apr 2027

ما هو موضوع هذه الدراسة؟

This study is focused on a rare condition called Neuromyelitis Optica Spectrum Disorder, or NMOSD. It's a condition where the body's immune system mistakenly attacks its own healthy cells, particularly in the brain and spinal cord, leading to a range of symptoms. This particular study is for children and teenagers aged between 2 and 17 years old who have been diagnosed with NMOSD and have a specific type of antibody in their blood.

The research aims to find out more about a new treatment called inebilizumab. It's important to understand how new medicines work in young people because their bodies can react differently compared to adults. The study will look at how the medicine is absorbed and used by the body, what effects it has, and how safe it is for this age group.

By carefully studying inebilizumab, researchers hope to gather important information that could help in the development of new and effective treatments for children and teenagers with NMOSD in the future. This kind of research is vital for improving the lives of those affected by rare conditions.

النقاط الرئيسية

  • This study is for children and teenagers with a specific type of NMOSD.
  • It's testing a new medicine called inebilizumab given intravenously.
  • The main goals are to check the medicine's safety and how it works in the body.
  • Participation involves regular clinic visits over a period of up to 80 weeks.
  • سيتم مراقبة صحتك عن كثب طوال فترة الدراسة.
  • يمكنك الانسحاب من الدراسة في أي وقت.

من قد يكون مؤهلاً؟

To be considered for this study, participants must be between 2 and 17 years old, weigh at least 15 kg (about 2 stone 5 pounds), and have a clear diagnosis of NMOSD. They also need to have tested positive for specific antibodies (called AQP4-IgG) in their blood and have experienced at least one NMOSD relapse in the past year, or two or more relapses in the past two years.

There are also some reasons why someone might not be able to join. For example, if they have other significant health problems affecting their liver, kidneys, or blood, or if they are currently taking part in another drug study. Also, if they have recently received certain other treatments for NMOSD or similar conditions, they might not be eligible. The study team will review all your medical information carefully to see if this study is right for you.

هل يمكن أن تناسبك هذه الدراسة؟

أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.

  1. هل عمرك بين 2 و 17 سنة؟
  2. Do you weigh at least 15 kg?
  3. Have you been diagnosed with Neuromyelitis Optica Spectrum Disorder?
  4. Have you had a positive blood test for AQP4-IgG antibodies?
  5. Have you experienced an NMOSD relapse in the last year, or two or more in the last two years?
  6. Are you currently free from other major health issues or recent specific treatments that might prevent your participation?
أجب عن كل سؤال لترى نتيجتك.

ماذا يتضمن المشاركة؟

If you join this study, you would receive the study medicine, inebilizumab, directly into your vein (intravenously) over a period of 28 weeks. The study involves several visits to the clinic. First, there's a screening period of up to 4 weeks to check if you're suitable. Then, during the 28-week treatment period, you'll have about 9 visits. After that, there's a follow-up period of about 52 weeks, with approximately 4 visits to monitor your health. The total time you would be involved in the study could be up to 80 weeks (about a year and a half). Your health will be regularly checked throughout this time to ensure your safety and monitor the effects of the treatment.

المخاطر والفوائد المحتملة

Participating in a clinical trial could offer the potential benefit of accessing a new treatment for your condition that is not yet widely available. However, there are also potential risks involved, as with any new medicine. These could include side effects from the medication or discomfort from procedures like blood tests or infusions. Your safety will be closely monitored by the study team, and you will receive regular medical check-ups. You are completely free to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (19)

  • UCSD Altman Clinical and Translational Research Institute Building
    الرمز البريدي المؤكد
    لا جولا، الولايات المتحدة· التوظيف
  • Loma Linda University Children's Hospital - PIN
    الرمز البريدي المؤكد
    لوما ليندا، الولايات المتحدة· التوظيف
  • مستشفى ماساتشوستس العام
    الرمز البريدي المؤكد
    بوسطن، الولايات المتحدة· التوظيف
  • مركز جامعة تكساس ساوثويسترن الطبي
    الرمز البريدي المؤكد
    دالاس، الولايات المتحدة· التوظيف
  • Hospital de Pediatría S.A.M.I.C.- Prof. Dr. Juan P. Garrahan
    الرمز البريدي المؤكد
    Parque Patricios, Argentina· التوظيف
  • Hospital Santa Izabel-Rua Floriano Peixoto 300
    الرمز البريدي المؤكد
    Salvador, Brazil· التوظيف
  • Hospital Sao Lucas Da Pontificia Universidade Catolica Do Rio Grande Do Sul (PUCRS)
    المدينة فقط
    Porto Alegre/RS, Brazil· التوظيف
  • CPQuali Pesquisa Clínica Sao Paulo
    الرمز البريدي المؤكد
    ساو باولو، البرازيل· التوظيف
  • Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
    الرمز البريدي المؤكد
    ساو باولو، البرازيل· التوظيف
  • Hospital For Sick Children
    الرمز البريدي المؤكد
    تورونتو، كندا· التوظيف
  • Centre Hospitalier Universitaire de Bicêtre
    الرمز البريدي المؤكد
    لو كريملين-بيسيتر، فرنسا· التوظيف
  • Erasmus MC Sophia Children's Hospital-Wytemaweg 80
    الرمز البريدي المؤكد
    روتردام، هولندا· التوظيف

أسئلة شائعة

What is NMOSD?

NMOSD is a rare condition where your body's immune system mistakenly attacks healthy cells, mainly in the brain and spinal cord.

What is inebilizumab?

Inebilizumab is the medicine being investigated in this study. It's a potential new treatment for NMOSD that aims to help manage the condition.

كيف سيتم إعطاء الدواء؟

The medicine will be given directly into a vein (intravenously), meaning through a drip.

كم من الوقت سأكون في الدراسة؟

If you join, the study participation could last for up to 80 weeks, which includes treatment and follow-up periods.

هل يمكنني مغادرة الدراسة في أي وقت؟

Yes, you have the right to withdraw from the study at any point, and it won't affect your ongoing medical care.

كيفية معرفة المزيد

Amgen Call Center

تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.

هل أنت مهتم بالمشاركة؟

سجل اهتمامك

شارك تفاصيلك وفريق البحث لـ "Study of Inebilizumab in Pediatric Subjects With Neuromyelit… "سيتواصل معك إذا كنت مؤهلاً. تحدث دائمًا إلى طبيبك قبل الموافقة على المشاركة.

نقاش

مناقشة المجتمع

مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.